rpoa9gk5

Property	Value
?:abstract	The unprecedented coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a serious threat to global public health. Development of effective therapies against SARS-CoV-2 is urgently needed. Here, we evaluated the antiviral activity of a remdesivir parent nucleotide analog, GS441524, which targets the coronavirus RNA-dependent RNA polymerase enzyme, and a feline coronavirus prodrug, GC376, which targets its main protease, using a mouse-adapted SARS-CoV-2 infected mouse model. Our results showed that GS441524 effectively blocked the proliferation of SARS-CoV-2 in the mouse upper and lower respiratory tracts via combined intranasal (i.n.) and intramuscular (i.m.) treatment. However, the ability of high-dose GC376 (i.m. or i.n. and i.m.) was weaker than GS441524. Notably, low-dose combined application of GS441524 with GC376 could effectively protect mice against SARS-CoV-2 infection via i.n. or i.n. and i.m. treatment. Moreover, we found that the pharmacokinetic properties of GS441524 is better than GC376, and combined application of GC376 and GS441524 had a synergistic effect. Our findings support the further evaluation of the combined application of GC376 and GS441524 in future clinical studies. Importance Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has seriously threatened global public health and economic development. Currently, effective therapies to treat COVID-19 are urgently needed. In this study, we assessed the efficacy of the preclinical inhibitors GC376 and GS441524 using a mouse-adapted SARS-CoV-2 infected mouse model for the first time. Our results showed that low-dose combined application of GC376 and GS441524 could effectively protect mice from HRB26M infection in the upper and lower respiratory tracts. Hence, the combined application should be developed and considered for future clinic practice.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/rpoa9gk5_hasAnnotation_C0021966> <https://research.tib.eu/covid-19/entity/rpoa9gk5_hasAnnotation_C0597107> <https://research.tib.eu/covid-19/entity/rpoa9gk5_hasAnnotation_C0936087> <https://research.tib.eu/covid-19/entity/rpoa9gk5_hasAnnotation_C1999216> <https://research.tib.eu/covid-19/entity/rpoa9gk5_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Shi%2C_Yuejun%3B_Shuai%2C_Lei%3B_Wen%2C_Zhiyuan%3B_Wang%2C_Chong%3B_Yan%2C_Yuanyuan%3B_Jiao%2C_Zhe%3B_Guo%2C_Fenglin%3B_Fu%2C_Zhen_F.%3B_Chen%2C_Huanchun%3B_Bu%2C_Zhigao%3B_Peng%2C_Guiqing>
?:doi	10.1101/2020.11.12.380931
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.11.12.380931>
?:externalLink	<https://doi.org/10.1101/2020.11.12.380931>
?:journal	bioRxiv
?:license	biorxiv
?:pdf_json_files	document_parses/pdf_json/5cb1faf7bee82d07de1bc21037166d23fb0541b9.json
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/rpoa9gk5_HAS_C0597107_INTERACTS_WITH_C5392142> <https://research.tib.eu/covid-19/entity/rpoa9gk5_HAS_C5203676_CAUSES_C5203670> <https://research.tib.eu/covid-19/entity/rpoa9gk5_HAS_C5392290_INTERACTS_WITH_C0030940>
?:sha_id	<https://research.tib.eu/covid-19/entity/5cb1faf7bee82d07de1bc21037166d23fb0541b9>
?:source	BioRxiv; WHO
?:title	The Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-13

Property

Value

?:abstract

The unprecedented coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a serious threat to global public health. Development of effective therapies against SARS-CoV-2 is urgently needed. Here, we evaluated the antiviral activity of a remdesivir parent nucleotide analog, GS441524, which targets the coronavirus RNA-dependent RNA polymerase enzyme, and a feline coronavirus prodrug, GC376, which targets its main protease, using a mouse-adapted SARS-CoV-2 infected mouse model. Our results showed that GS441524 effectively blocked the proliferation of SARS-CoV-2 in the mouse upper and lower respiratory tracts via combined intranasal (i.n.) and intramuscular (i.m.) treatment. However, the ability of high-dose GC376 (i.m. or i.n. and i.m.) was weaker than GS441524. Notably, low-dose combined application of GS441524 with GC376 could effectively protect mice against SARS-CoV-2 infection via i.n. or i.n. and i.m. treatment. Moreover, we found that the pharmacokinetic properties of GS441524 is better than GC376, and combined application of GC376 and GS441524 had a synergistic effect. Our findings support the further evaluation of the combined application of GC376 and GS441524 in future clinical studies. Importance Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has seriously threatened global public health and economic development. Currently, effective therapies to treat COVID-19 are urgently needed. In this study, we assessed the efficacy of the preclinical inhibitors GC376 and GS441524 using a mouse-adapted SARS-CoV-2 infected mouse model for the first time. Our results showed that low-dose combined application of GC376 and GS441524 could effectively protect mice from HRB26M infection in the upper and lower respiratory tracts. Hence, the combined application should be developed and considered for future clinic practice.

is ?:annotates of